Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of atezolizumab, bevacizumab, and acetylsalicylic acid in recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal adenocarcinoma
2015-004601-17Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, bevacizumab and aspirin in Malignant Ovarian Tumor, Oviductal Adenocarcinoma and primary peritoneal adenocarcinoma (PPC) (5 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Progression-free survival rate at 6 months and Safety. Started Apr 2017; status: completed.
02
Drugs
atezolizumabbevacizumabaspirin
03
Conditions
Malignant Ovarian TumorOviductal Adenocarcinomaprimary peritoneal adenocarcinoma (PPC)
Beyond the preview
Go deeper on 2015-004601-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004601-17.